RE:RE:RE:RE:RE:ViaCyte CEO Retired Sept 2020; no replacement so farBioTeck wrote: https://www.the-scientist.com/bio-business/biotechs-race-to-develop-stem-cell-treatments-for-diabetes--66100
Semma is also developing macroencapsulation methods, including a very thin device that in prototype form is about the size of a silver dollar coin. The device is deceptively simple but it allows us to put [in] a fully curative dose of islets, Sanna says. It protects the cells from the immune system with a particular type of membrane that keeps the immune system out, allowing for very fast and precise exchange of glucose and insulin in the body. The company expects to launch a clinical trial of the device in early 2021.
Funny how Bioteck loves to fear monger and his hate for Sernova is so clear . First you knock how much directors bought and say it’s nothing . I agree it is not significant but it’s a start . Secondly Bioteck says Sernova will not be a cure fir diabetes and that he invests for other potential indications, but at the same time says the Hemophilia/ Hemacure news did nothing for the stock price . Such contradiction . Yes they spent money on IR which was a substantial amount of money . Midam was the lead order for the last disastrous financing Matthews arranged , part of the condition of financing was to invest $500,000 US in their IR campaign or no lead order. What you fail to mention is that Matthews is not involved and the recent financing was above sp by institutional investors. No sleepy IR firms or greasy pockets to be greased or cheap pp.
The kicker Bioteck is that your contradiction is so vain, that you copy and paste from July 2019 article which talks about Semma and Viacyte in the same breath . Where is Viacyte now ? I hear Semma is having trouble with consistency and efficacy in reproduction of their cells. Their immune coating on their device is unproven. I don’t care how much money Semma has , they still have to show preclinical studies in animal models, pass bioethics and get approval for a trial design by Fda before a trial can actually begin . Years away. It is easy to be an armchair quarterback Bioteck and say have not even enrolled all 7 patients in the study . How do you know how many patients are enrolled or know any of the clinical results? Do you know how difficult it is to find an hypoglycaemic patient that produces absolutely no c peptide at all? That has to be proven for at least 6 months to be even considered enrolled in a study ? Hospitals have been closed due to pandemic since March but easy to ou5 down the study. Semma is also in the same vote .
So from the very same article you copy and pasted Semma propaganda, Tomei is quoted and referred to as a top scientist in the field of immunosuppresion of Beta insulin cells! Guess who outright owns this novel cutting edge immunosuppresion technology ? Sernova does and it owns the world wide rights and patents and licences for it ! Here is the quote :
“Nevertheless, there’s growing confidence throughout the field that these problems will be solved, and soon. “We have the islet cells now,” says Alice Tomei, a biomedical engineer at the University of Miami who directs DRI’s Islet Immunoengineering Laboratory.
These stem cell companies are working really hard to try to get FDA clearance on the cells.”
Tomei has enough recent work to present to the Fda to push for a clinical trial with stem cells coated Toneis technology using Setnovas pouch in Type 2 diabetic patients without immunosuppresion. That is where the money raised in the recent po will be goin. We know the pouch is safe, first patient shows excellent clinical results initially . We wait for more clinical update on the need for insulin independence on the first patient , and also subsequent results on additional patients . In addition Sernova has multiple indications for the pouch.
Keep fear mongering Bioteck.